Plain-English translation of NCT06585007 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether men with castration-resistant prostate cancer—a form that keeps growing despite hormone therapy—live longer when they receive targeted radiation or surgery to specific areas where the cancer is spreading. Researchers will compare this approach against continuing standard medications alone. The goal is to help doctors understand whether removing or treating small areas of new cancer growth can improve survival.
Some men with advanced prostate cancer develop only a few new areas of spread rather than widespread disease everywhere. Doctors wonder whether aggressively treating these limited spots—using radiation or surgery—might slow the cancer down and help men live longer, rather than just using medications alone.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to one of two groups. One group continues standard medications (either as they are or with new medications added). The other group receives targeted radiation or surgery to the areas where cancer is spreading, while also continuing their current medications. You will meet with a multidisciplinary team (urologists, radiologists, and other specialists) before randomization to decide on your specific treatment plan. The study will track your health and cancer response over time to see if the additional targeted treatment helps you live longer.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Belgium
Phase
Large-scale testing
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment target
~246 participants
Started
December 2023
Primary completion
January 2029
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kato Rans, MD
Universitaire Ziekenhuizen KU Leuven
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.